JPX · 3391.T
Tsuruha Holdings Inc.
¥2,236+¥52 (+2.38%)
Tsuruha Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.29% below the high.
Loading market information…
OTC · FOGCF · USD
Stock price
Quote as of Apr 21, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Avisa Diagnostics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Avisa Diagnostics Inc. is a medical device company currently in its clinical development phase. The company is advancing the Avisa BreathTest, an innovative drug-device biomarker platform. This technology enables the exceptionally rapid identification and quantitative monitoring of virulent bacterial pathogens, activated when patients inhale or ingest its proprietary diagnostic compounds. Avisa Diagnostics has successfully established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis, and community-acquired pneumonia. Currently, the firm is concentrating its efforts on pivotal trials addressing Post-COVID-19 bronchiectasis and ventilator-associated pneumonia. Avisa Diagnostics Inc. is headquartered in Santa Fe, New Mexico.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥2,236+¥52 (+2.38%)
Tsuruha Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.29% below the high.
CHF 71.10-CHF 0.40 (-0.56%)
Basilea Pharmaceutica AG’s quoted price sits in the upper half of its reported 52-week range, 6.2% below the high.
$24.57$0.00 (0.0%)
Torii Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
SEK 205.00+SEK 0.80 (+0.39%)
Xvivo Perfusion AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.88% below the high.
$0.55$0.00 (0.0%)
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.: Healthcare · Drug Manufacturers - Specialty & Generic.
HK$5.65+HK$0.12 (+2.08%)
Beijing Tong Ren Tang Chinese Medicine Company Limited’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
A$0.91+A$0.03 (+2.84%)
PolyNovo Limited’s quoted price sits in the lower half of its reported 52-week range, 34.89% below the high.
SEK 19.00-SEK 0.14 (-0.73%)
Swedencare AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 52.32% below the high.
